Business
PDS Reports Q3 2021 Results & Business Update
PDS Reports Q3 2021 Results & Business Update.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 9835R\n NetScientific PLC\n 10 November 2021\n \n \n \n \n NetScientific plc\n \n \n (\"NetScientific\", the \"Group\" or the \"Company\")\n \n \n \n \n \n PDS Provides Business Update and Reports Q3 2021 Financial Results\n \n \n \n \n \n London, UK - 10 November 2021 - NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), announced its financial results for the quarter ended September 30, 2021 (\"the Period\") and provided a business update on its conference call today.\n \n \n \n \n PDS Highlights for the Period:\n \n \n · \n Achieved several milestones in the VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® for recurrent and/or metastatic human papillomavirus (HPV)16-associated head and neck cancer. These milestones include:\n \n \n o \n Achievement of the preliminary safety benchmark for the first 12 patients\n \n \n o \n Completion of enrolment for the first stage of the checkpoint inhibitor naïve arm (1st line treatment of recurrent or metastatic head and neck cancer).\n \n \n o \n Initiated enrolment of the second arm of the study addressing checkpoint inhibitor refractory patients (2nd line treatment of recurrent or metastatic head and neck cancer)\n \n \n · \n Completed a licensing agreement with the National Cancer Institute (NCI) for intellectual property related to the NCI's proprietary T-cell receptor gamma alternate reading frame protein (TARP) tumour antigen for use in PDS0102.\n \n \n o \n PDS0102 is being developed to treat prostate cancer, breast cancer and acute myeloid leukaemia or AML.\n \n \n o \n PDS0102 has demonstrated powerful induction of TARP-specific killer T-cells in preclinical studies.\n \n \n · \n Entered agreement to license COBRA (Computationally Optimized Broadly Reactive Antigen) antigens from the University of Georgia for use in the development of PDS0202, a novel Versamune®-based universal flu vaccine.\n \n \n · \n Announced temporary administrative suspension of enrolment into the NCI-led study of the PDS0101 triple combination. PDS Biotech continues to be in contact with the NCI. Treatment of already enrolled patients...